Page last updated: 2024-08-21

fluorobenzenes and Anterior Cerebral Circulation Infarction

fluorobenzenes has been researched along with Anterior Cerebral Circulation Infarction in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hasegawa, Y; Kataoka, K; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Kuratsu, J; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K	1
Bassetti, CL; Hermann, DM; Kilic, E; Kilic, U; Wang, Z; Xing, H	1

Other Studies

2 other study(ies) available for fluorobenzenes and Anterior Cerebral Circulation Infarction

Article	Year
Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation. Brain research, 2013, Jun-26, Volume: 1519 Topics: Animals; Brain Infarction; Brain Ischemia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectodysplasins; Encephalitis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Glycoproteins; Microfilament Proteins; NADPH Oxidase 2; NADPH Oxidases; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Pyrimidines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation	2013
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience, 2005, Volume: 134, Issue:3 Topics: Animals; Blotting, Western; Brain Infarction; Brain Ischemia; Cell Count; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Reperfusion; Rosuvastatin Calcium; Staining and Labeling; Sulfonamides; Time Factors	2005

Article

Year

Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation.

Brain research, 2013, Jun-26, Volume: 1519

Topics: Animals; Brain Infarction; Brain Ischemia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectodysplasins; Encephalitis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Glycoproteins; Microfilament Proteins; NADPH Oxidase 2; NADPH Oxidases; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Pyrimidines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation

2013

Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.

Neuroscience, 2005, Volume: 134, Issue:3

Topics: Animals; Blotting, Western; Brain Infarction; Brain Ischemia; Cell Count; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Reperfusion; Rosuvastatin Calcium; Staining and Labeling; Sulfonamides; Time Factors

2005